---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-093520"
form_type: "8-K"
ticker: "APTN"
cik: "0001938571"
company_name: "ADAPTIN BIO, INC."
filed_at: "2026-08-25T20:10:32+00:00"
generated_at: "2026-08-25T20:11:27.651692+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Adaptin Bio opens enrollment in Phase 1 trial of APTN-101 for glioblastoma

## Summary
- Enrollment opened in Phase 1 open-label dose-escalation trial of APTN-101 (BRiTE T-cell engager) for EGFRvIII-positive GBM, at Duke University, up to 15 adult patients.
- Primary endpoint is proportion of patients with dose-limiting toxicity per dose level; secondary endpoints include pharmacokinetics and objective response rate (modified RANO).
- Preclinical data: APTN-101 showed >7-fold increase in brain distribution vs EGFRvIII engager alone and complete tumor eradication in 70-80% of mice models.
- GBM is ~15,000 new U.S. cases/year; market valued at $3.02B (2025), projected $4.44B by 2030 (8% CAGR).

## SEC filing metadata
- accession: 0001213900-26-093520
- form_type: 8-K
- ticker: APTN
- cik: 0001938571
- company_name: ADAPTIN BIO, INC.
- filed_at: 2026-08-25T20:10:32+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938571/000121390026093520/0001213900-26-093520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938571/000121390026093520/ea0303128-8k_adaptin.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-093520
- JSON: https://secwatch.observer/filing/0001213900-26-093520.json
- Plain text: https://secwatch.observer/filing/0001213900-26-093520.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.